Amarantus Biosci (AMBS) Stock Price & Analysis
AMBS Stock Chart & Stats
- Day’s Range
- $0.01 - $0.01
- 52-Week Range
- N/A
- Previous Close
- $0.01
- Volume
- 54.12K
- Average Volume (3M)
- 1.36M
- Market Cap
- $630
- Enterprise Value
- $19.18T
- Total Cash (Recent Filing)
- $0
- Total Debt (Recent Filing)
- $19.12M
- Price to Earnings (P/E)
- ―
- Beta
- 120.57
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
AMBS FAQ
What is Amarantus Biosci’s market cap?
When is Amarantus Biosci’s upcoming earnings report date?
Is Amarantus Biosci overvalued?
Does Amarantus Biosci pay dividends?
What is Amarantus Biosci’s EPS estimate?
How many shares outstanding does Amarantus Biosci have?
Which hedge fund is a major shareholder of Amarantus Biosci?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Amarantus Biosci
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Wesley Commissiong
- Employees
- 12
- Website
- www.amarantus.com
- Address
- 45 Wall Street, New York City, NY, 10005, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 3 |
| Technical Analysis | 2 | 1 | 1 |
| Moving Averages | 2 | 2 | 2 |